受体
多克隆抗体
抗体
癌症研究
下调和上调
单克隆抗体
信号转导
细胞凋亡
酪氨酸激酶
表位
表皮生长因子受体
免疫学
生物
细胞生物学
生物化学
基因
作者
Narjara González Suárez,Gretchen Bergado Báez,Mabel Rodríguez,Amelia Gutiérrez Pérez,Lisset Chao García,Diana Fernández,Judith Raymond Pous,Belinda Sánchez Ramírez
出处
期刊:Oncotarget
[Impact Journals, LLC]
日期:2017-08-03
卷期号:8 (47): 82872-82884
被引量:7
标识
DOI:10.18632/oncotarget.19958
摘要
The human epidermal growth factor receptor (HER1) and its partner HER2 are extensively described oncogenes and validated targets for cancer therapy. However, the effectiveness of monospecific therapies targeting these receptors is hampered by resistance emergence, which is frequently associated with the upregulation of other members of HER family. Combined therapies using monoclonal antibodies or tyrosine kinase inhibitors have been suggested as a promising strategy to circumvent this resistance mechanism. We propose an alternative approach based on simultaneous inactivation of HER1 and HER2 by multi-epitope blockade with specific polyclonal antibodies induced by vaccination. Elicited antibodies impaired both receptors activation and induced their degradation, which caused the inhibition of down-signaling cascades. This effect was translated into cell cycle arrest and apoptosis induction of human tumor cells. Elicited antibodies were able to reduce the viability of a panel of human tumor lines with differential expression levels of HER1 and HER2. The most significant effects were obtained in the tumor lines with lower expression levels of both receptors. These new insights would contribute to the rational design of HER receptors targeting multivalent vaccines, as an encouraging approach for the treatment of cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI